Cesca Therapeutics Inc. (Nasdaq:KOOL)

Biotechnology ResearchCalifornia, United States51-200 Employees

Cesca Therapeutics is a world-leader in the research, development, and commercialization of automated systems for use in the separation, processing and cryo-preservation of cells from blood, bone marrow and other tissues. 

Cesca is developing its next generation automated CAR-TXpress™ solution that isolates and processes T-cells, using patented buoyancy-activated cell sorting (X-BACS™), resulting in superior purity, recovery and viability of cells used for the treatment of cancer, such as CAR T-cell therapy.  Our patented X-BACS process employs microscopic bubbles that bear antibodies on their surface, enabling them to bind specifically to a desired target cell type.  A major industry concern is the high cost and time to manufacture CAR T-cell therapies due to a manually intensive production process.  Cesca believes its automated CAR-TXpress solution will enable the more efficient, cost-effective and scalable production of these novel cell-based immunotherapies and help to expand the market for these treatments.  Cesca intends to sell the CAR-TXpress solution as well as seek partnerships with industry and academic iscalnstitutions focused on CAR-T and other immunotherapy approaches.

Sign up for free to view info

Email Format Employee directory